Top Ten most popular articles on Pharmafile.com this week
pharmafile | September 15, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cosentyx, Eli Lilly, Martin Skreli, Teva, pharma, top ten
This week has been a particularly eventful one for the industry: among our top stories, Martin Shkreli finally heads to jail after one outrageous act too many, soliciting violence against Hilary Clinton by offering a monetary reward for her hair; Eli Lilly reveals that it is to action huge staff cuts, slashing away almost 10% of its global workforce, and Teva finally announces a new CEO, after much speculation and quashed rumours that AstraZeneca CEO Pascal Soirot would be stepping into the role.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. BMS hit by clinical trial hold from FDA
The FDA has placed a partial hold on clinical trials involving Bristol-Myers Squibb’s immunotherapy treatment, Opdivo, when used in combination with certain medicines in treating patients with multiple myeloma.
9. Aspirin may be a cost-effective alternative to fillings
Researchers from Queen University, Belfast, have discovered that aspirin may be able to reverse the effects of tooth decay. In tests in the laboratory, studies found that aspirin was able to stimulate stem cells in the teeth in order to repair the dentine lost due to tooth decay.
‘8. Pharma bro’ Shkreli heads to jail
Martin Shkreli’s habit of being unable to stay out of the headlines continues, although this time with the repercussion that he will now go to jail. He generated controversy this time by posting a message on Facebook offering a $5,000 reward for a strand of Hillary Clinton’s hair.
7. J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion’s stock
Johnson and Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to develop the firm’s hepatitis C drug pipeline.
6. Balancing the R&D equation: Measuring the return from pharmaceutical innovation
Following Deloitte’s anaylsis of th return on R&D spend by biopgramaceutical companies, this report reveals the key difficulties faced, as well as how approches during drug development can boost the success of an asset.
5. Amgen and AstraZeneca’s experimental drug cuts asthma exacerbations by up to 71%
An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca has met its primary endpoint in Phase 2b trials, demonstrating a significant reduction in annual exacerbation rates in patients with severe, uncontrolled asthma.
4. Questions raised after two deaths in AbbVie arthritis study
AbbVie’s big plans for its new rheumatoid arthritis drug have taken a knock after the release of Phase 3 revealed two patients deaths in the trial.
3. Lily announces massive staff cuts of 3,500 to “streamline business”
In a drastic bid to “streamline business, invest in new medicines and drive”, Eli Lilly has announced major staff cuts to the tune of 3,500 positions, or a massive 8.5% of its global workforce.
2. Teva finally announces successful CEO appointment
Teva has announced that its protracted search for a new CEO has finally come to end, as it revealed the appointment of Kåre Schultz. The decision to bring in Schultz means that the CEO search comes to a close for the company after seven months, with several twists and turns occurring over this period.
1. Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance
Novartis has unveiled new Phase 3 data for Cosentyx (secukinumab) evidencing its long term skin clearance benefits and safety profile in the treatment of psoriasis.
Related Content
Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
